Solid Biosciences (SLDB) Common Equity (2017 - 2026)

Solid Biosciences has reported Common Equity for 10 years, with the latest figure at $374.1 million in Q1 2026.

• Quarterly Common Equity rose 27.06% year-over-year to $374.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $374.1 million (up 27.06% YoY) and the FY2025 annual result came in at $180.0 million, up 31.16% from the prior year.
• Common Equity advanced to $374.1 million in Q1 2026 per SLDB's latest filing, from $180.0 million in the prior quarter.
• Over five years, Common Equity peaked at $374.1 million in Q1 2026 and troughed at $126.5 million in Q4 2023.
• A 5-year average of $197.3 million and a median of $183.8 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity tumbled 40.25% in 2023, then jumped 39.74% in 2025.
• Over 5 years, Common Equity stood at $211.7 million in 2022, then sank by 40.25% to $126.5 million in 2023, then grew by 8.51% to $137.2 million in 2024, then jumped by 31.16% to $180.0 million in 2025, then jumped by 107.84% to $374.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $374.1 million, $180.0 million, and $217.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.